文献速递造血干细胞移植与细胞治疗白血病

供者年龄决定40岁以上急性白血病患者接受单倍体造血细胞移植的结局

Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation.
PubMed 文献 · Am J Hematol · 2017-12-06

该多国登记回顾性分析纳入2005至2015年间接受单倍体造血细胞移植的1270例急性髓系白血病和急性淋巴细胞白血病患者,评估供者年龄和亲属关系对结局的影响。供者年龄超过40岁时,40岁以上患者的非复发死亡率、无白血病生存和总生存均更差;子女供者年龄超过35岁时非复发死亡率亦增加。40岁以下患者中供者年龄和亲属关系多无临床影响。

要点

  • 供者年龄超过40岁时,40岁以上急性白血病患者单倍体移植的非复发死亡率更高(HR=1.86)。
  • 供者年龄超过40岁时,40岁以上患者无白血病生存(HR=1.59)和总生存(HR=1.74)更差。
  • 子女供者年龄超过35岁时,患者非复发死亡率增加(HR=1.82),无白血病生存和总生存更差。

核心结论

  • 供者年龄和亲属关系是急性白血病患者单倍体造血细胞移植结局的显著决定因素。

研究设计与样本

  • 欧洲血液和骨髓移植学会急性白血病工作组多国登记回顾性分析,纳入2005至2015年间接受单倍体造血细胞移植的1270例急性髓系白血病和急性淋巴细胞白血病患者。

主要发现

  • 供者年龄超过40岁时,40岁以上患者的非复发死亡率更高(HR=1.86,95%CI 1.18-2.94,P=.007),无白血病生存更差(HR=1.59,95%CI 1.13-2.24,P=.007),总生存更差(HR=1.74,95%CI 1.22-2.47,P=.002)。
  • 子女供者年龄超过35岁时,患者非复发死亡率增加(HR=1.82,95%CI 1.13-2.9,P=.01),无白血病生存更差(HR=1.5,95%CI 1.05-2.13,P=.03),总生存更差(HR=1.5,95%CI 1.04-2.15,P=.03)。
  • 40岁以下患者中,供者年龄和亲属关系多无临床影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Haploidentical hematopoietic cell transplantation (haplo-HCT) is being increasingly used in acute leukemia patients as an alternative transplant modality when matched sibling or matched unrelated donors are unavailable. As several potential haploidentical relative donors are typically available for a given patient, optimizing donor selection to improve clinical outcome is crucial. The impact of donor age and kinship on the outcome of acute leukemia patients is not clearly established in this setting. Using the multinational registry of the acute leukemia working party of the European society for blood and marrow transplantation we retrospective analyzed the clinical outcome of 1270 acute myeloid leukemia and acute lymphoblastic leukemia patients who underwent haplo-HCT between 2005 and 2015. Patients over the age of 40 were significantly affected by increasing donor age resulting in higher non-relapse mortality (NRM) [Hazard ratio (HR)=1.86, confidence interval (CI) 95%, 1.18-2.94; P = .007], inferior leukemia-free survival (LFS) (HR = 1.59, CI 95%, 1.13-2.24; P = .007), and overall survival (OS) (HR = 1.74, CI 95%, 1.22-2.47; P = .002) when donors were over the age of 40. Additionally, kinship was found to be prognostically significant as patients transplanted from children donors over the age of 35 experienced an increased rate of NRM (HR = 1.82, CI 95%, 1.13-2.9; P = .01), inferior LFS (HR = 1.5, CI 95%, 1.05-2.13; P = .03), and OS (HR = 1.5, CI 95%, 1.04-2.15; P = .03). For patients younger than 40 years, donor age and kinship were mostly not clinically impactful. Our data establish donor age and kinship as significant determinants of outcome following haplo-HCT for acute leukemia patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Canaani J, Savani BN, Labopin M, et al. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. Am J Hematol. 2017. PMID: 29114918. doi:10.1002/ajh.24963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。